May 23, 2018 / 9:42 PM / 3 months ago

BRIEF-Epigen Biosciences Says Enters Collaboration Agreement With Novo Nordisk A/S

May 23 (Reuters) - Novo Nordisk A/S:

* EPIGEN BIOSCIENCES SAYS ENTERS COLLABORATION TO LICENSE ITS LPA1 RECEPTOR SMALL MOLECULE PROGRAM TO NOVO NORDISK A/S FOR UP TO USD 200 MILLION

* EPIGEN BIOSCIENCES SAYS CO WILL ALSO BE ELIGIBLE TO GET TIERED ROYALTIES AND MILESTONES ON WORLDWIDE SALES OF PRODUCTS THAT ARISE FROM COLLABORATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below